That all changed over the past year with the approval of Yervoy™ and Zelboraf™. In this issue of The Melanoma Letter, Dr. Paul Chapman discusses the exciting, newly FDA-approved drug Zelboraf ...

Vemurafenib (Zelboraf™) was the second drug approved for metastatic melanoma this year. In March, the FDA approved ipilimumab (Yervoy™), a monoclonal antibody that binds to CTLA-4, which ...

Plexxikon had great expectations for Zelboraf when it first reached the market, pegging peak sales at around $700 million a year, but it never reached those heights with annual sales in the region ...

The National Institute for Health and Clinical Excellence has backed the use of Zelboraf in appropriate melanona patients, two months after it was turned down by the Scottish Medicines Consortium ...

Since Roche’s Zelboraf gained FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, ...

Cancer Research UK, The University of Manchester and Roche Products Ltd (‘Roche’), today (Wednesday 23rd), announce that they have opened a multi-drug, precision medicine trial for people with rare ...

She served in marketing and sales roles for AVASTIN® (bevacizumab), TARCEVA® (erlotinib), ZELBORAF® (vemurafenib), and TECENTRIQ. Prior to Genentech, Dr. Dillon was a Senior Consultant at the ...

this infrastructure award supports a network of 18 adult centres (of excellence) and 11 paediatric locations throughout the UK. *****Combination treatments Cotellic + Zelboraf and Herceptin + Perjeta.

The U.S. Food and Drug Administration (FDA) on Wednesday approved Zelboraf (vemurafenib) to treat patients with late-stage (metastatic) or unresectable melanoma, the most dangerous type of skin cancer ...

She served in marketing and sales roles for AVASTIN® (bevacizumab), TARCEVA® (erlotinib), ZELBORAF® (vemurafenib), and TECENTRIQ. Prior to Genentech, Dr. Dillon was a Senior Consultant at the ...